Moderna's COVID-19 vaccine candidate has longer shelf life, to remain stable at 2° to 8°C

• Following positive efficacy data, Moderna (NASDAQ:MRNA) reports that its COVID-19 vaccine candidate, mRNA-1273 remains stable at 2° to 8°C (36° to 46°F), the temperature of a standard home or medical refrigerator, for 30 days.
• mRNA-1273 remains stable at -20° C (-4°F) for up to six months, at refrigerated conditions for up to 30 days and at room temperature for up to 12 hours.
• Stability testing supports this extension from an earlier estimate of 7 days.
• “We believe that our investments in mRNA delivery technology and manufacturing process development will allow us to store and ship our COVID-19 vaccine candidate at temperatures commonly found in readily available pharmaceutical freezers and refrigerators,” said Juan Andres, Chief Technical Operations and Quality Officer.
• The vaccine will not require onsite dilution or special handling.
• When compared to peers, Pfizer's (NYSE:PFE) vaccine must be stored frozen at negative 94 degrees Fahrenheit (-70° C), most likely needing dry ice (-109 degrees Fahrenheit) for shipment.
• Johnson & Johnson's (NYSE:JNJ) vaccine, if successful, is expected to be stable at refrigerated temperatures of 35.6 - 46.4 degrees Fahrenheit (2°C - 8°C) for at least three months and for two years at -20 °C.
• CureVac's (NASDAQ:CVAC) CVnCoV, is stable for at least three months at +41 degrees Fahrenheit (+5 Celsius) which is standard refrigerator temperature. It is also stable for up to 24 hours at room temp in a ready-to-use setting.
• Sanofi (NASDAQ:SNY) and GlaxoSmithKline's (NYSE:GSK) two-dose recombinant protein vaccine can be stored between 35.6 - 46.4 degrees Fahrenheit (28°C - 8°C).